Targeting dysfunctional healing with immune-modulating peptides

Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that target dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses.

Xinnate is conducting an ambitious research and clinical program for TCP-25, which includes a phase 1b clinical study in patients with Epidermolysis Bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.

The idea

Using the body’s natural defence to promote healing

Read more

The opportunity

Next generation cost-efficient treatment in a growing market of wounds and skin inflammation

Read more

The foundation

Proven effect based on 15 years of internationally recognized research

Read more